Clinical Trials in Salt Lake City

Showing 4841-4860 of 16,694 trials

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

NCT05609942

The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies. The main questions it aims to answer are: * Determine Recommended Dose of elenestinib (BLU-263) monotherapy for participants with AdvSM * Safety and tolerability of elenestinib (BLU-263) monotherapy * Efficacy of elenestinib (BLU-263) monotherapy in participants with AdvSM * Determine Recommended Dose of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM * Safety and tolerability of elenestinib (BLU-263) in combination with azacitidine * Efficacy of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM The estimated study duration for each participant will be approximately 4 years: 2 years of treatment followed by 2 years of follow-up. Participants may be required to attend monthly visits for the first six months, followed by quarterly visits for the remainder of the study.

Advanced Systemic Mastocytosis

Blueprint Medicines Corporation9 participantsStarted Sep 2023

Palo Alto, California, United States • Boston, Massachusetts, United States • Ann Arbor, Michigan, United States +8 more locations

TERMINATEDPhase 3< 1 mile

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

NCT03192215

Objectives * Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. * Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Stroke

Columbia University1,015 participantsStarted Jan 2018

Birmingham, Alabama, United States • Mobile, Alabama, United States • Chandler, Arizona, United States +174 more locations

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Find Trials by Condition in Salt Lake City

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

The SHUNT-V Study for Varices

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

Clinical Outcomes of Bilateral Clareon Vivity in Post-Refractive Patients

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

MRI to Characterize and Predict CF Liver Disease in PUSH Cohort

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

Amivantamab in Adenoid Cystic Carcinoma

Calypso Knee System Clinical Study

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors